Neumora Therapeutics (NMRA) Debt Ratio (2025 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Debt Ratio of 0.34 for Q1 2026, up 20.58% quarter-over-quarter from 0.29 in Q4 2025.
Analysis
Neumora Therapeutics (NMRA) Debt Ratio (2025 - 2026) Analysis & Trends
Neumora Therapeutics' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.34 for Q1 2026.
- In Q1 2026, Debt Ratio changed N/A year-over-year to 0.34; the TTM figure through Mar 2026 stood at 0.34 (changed N/A YoY), while the FY2025 annual figure was 0.29, changed N/A from the prior year.
- Debt Ratio for Q1 2026 stood at 0.34, up from 0.29 in the prior quarter.
- The five-year high for Debt Ratio was 0.34 in Q1 2026, with the low at 0.09 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.05 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.47 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.26 |
| 10 | Neumora Therapeutics | 243.49 Mn | 243.49 Mn | - | 0.42 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.42 |
| Mar 31, 2026 | 0.34 |
| Dec 31, 2025 | 0.29 |
| Sep 30, 2025 | 0.11 |
| Jun 30, 2025 | 0.09 |